Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
Related Articles
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Robotic Partial Cystectomy Safe After Neoadjuvant Chemotherapy for MIBC – Oncology Nurse Advisor
Small retrospective study showed that the procedure achieved negative surgical margins in all cases, with no patients requiring salvage cystectomy.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
SEQUOIA Extended Follow-Up Supports Initial Findings in CLL/SLL | Blood Cancers Today
After five years of follow-up in the phase 3 SEQUOIA study, first-line zanubrutinib treatment continues to demonstrate an improvement in progression-free survival in CLL versus…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
FY25 FDA Broad Agency Announcement – Q&A Session
FY25 FDA Broad Agency Announcement – Question and Answer Session
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
